To determine whether interruption of Qa-1b/NKG2A inhibitory signaling might have therapeutic potential in the context of CAR-T therapy, we introduced an antibody targeting NKG2A into leukemia-bearing mice concurrently with the introduction of CAR-T cells (Fig. 4e, f and Supplementary Fig. 6f). This evidence concerns the gene KLRC1 and leukemia.